VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
Cancer Chemother Pharmacol
; 7(2-3): 209-10, 1982.
Article
em En
| MEDLINE
| ID: mdl-7083461
ABSTRACT
Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Podofilotoxina
/
Carcinoma Broncogênico
/
Ciclofosfamida
/
Etoposídeo
/
Neoplasias Pulmonares
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Cancer Chemother Pharmacol
Ano de publicação:
1982
Tipo de documento:
Article